Clinical trial · Interventional
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
Research for Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors - PACAomics / IPC 2011-004
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat. Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month. The aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response. This project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Tumor | Pancreatic Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| suspected pancreatic tumor | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- suspected pancreatic tumor
- description
- Realization of pancreatic tumor biopsy and blood samples
- interventionNames
- Procedure: suspected pancreatic tumor
Primary outcomes (1)
- measure
- Biomarkers
- timeFrame
- within twenty four hours
- description
- Genomics, transcriptomics and proteomics analyses to determine presence or absence of biomarkers
Secondary outcomes (1)
- measure
- Histology
- timeFrame
- within twenty four hours
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Suspicion of pancreatic adenocarcinoma * Patient \> 18 years old * Social Security affiliation * Signed informed consent Exclusion Criteria: * Patient in emergency situation * Major person being the object of a legal protective measure or unable to express its consent
References
Publications (10)
- RESULTFraunhoffer NA, Abuelafia AM, Chanez B, Bigonnet M, Gayet O, Roques J, Chuluyan E, Dusetti N, Iovanna J. Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Cancer Commun (Lond). 2022 Nov;42(11):1212-1216. doi: 10.1002/cac2.12365. Epub 2022 Sep 30. No abstract available. PMID 36178036
- RESULTFraunhoffer NA, Abuelafia AM, Dusetti N, Iovanna J. Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. Cancer Commun (Lond). 2022 Oct;42(10):1028-1031. doi: 10.1002/cac2.12335. Epub 2022 Jul 18. No abstract available. PMID 35848462
- RESULTFaleiro I, Roberto VP, Demirkol Canli S, Fraunhoffer NA, Iovanna J, Gure AO, Link W, Castelo-Branco P. DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study. Cancers (Basel). 2021 Dec 17;13(24):6354. doi: 10.3390/cancers13246354. PMID 34944974
- RESULTRizzuti B, Lan W, Santofimia-Castano P, Zhou Z, Velazquez-Campoy A, Abian O, Peng L, Neira JL, Xia Y, Iovanna JL. Design of Inhibitors of the Intrinsically Disordered Protein NUPR1: Balance between Drug Affinity and Target Function. Biomolecules. 2021 Oct 3;11(10):1453. doi: 10.3390/biom11101453. PMID 34680086
- RESULTMohamed Abd-El-Halim Y, El Kaoutari A, Silvy F, Rubis M, Bigonnet M, Roques J, Cros J, Nicolle R, Iovanna J, Dusetti N, Mas E. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. EBioMedicine. 2021 Sep;71:103541. doi: 10.1016/j.ebiom.2021.103541. Epub 2021 Aug 20. PMID 34425307
- RESULTAdjuto-Saccone M, Soubeyran P, Garcia J, Audebert S, Camoin L, Rubis M, Roques J, Binetruy B, Iovanna JL, Tournaire R. TNF-alpha induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. Cell Death Dis. 2021 Jun 25;12(7):649. doi: 10.1038/s41419-021-03920-4.